Could immunotherapy let surgeons do less without hurting survival?
NCT ID NCT07320690
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether people with advanced head and neck cancer who respond to immunotherapy can safely have a smaller, less invasive surgery than usual. The goal is to preserve organ function and quality of life without lowering the chance of survival. About 356 participants will be randomly assigned to either standard surgery or a reduced surgery based on post-immunotherapy tumor boundaries.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- immunotherapy (neoadjuvant) followed by de-escalation surgery
- What this could lead to
- If successful, this approach could allow many patients to have smaller, less disfiguring surgeries while still controlling their cancer.
- What could go wrong
- This is a Phase 3 trial, but it is not yet recruiting. The non-inferiority design means it aims to show that less surgery is not worse than standard surgery, but there is a risk that survival could be slightly worse.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Ninth Peolple's Hospital
Shanghai, Shanghai Municipality, 200000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Pre-Surgery immunotherapy prime the immune system to fight head and neck cancer?
- Can a new drug boost the power of chemoradiation against head and neck cancer?
- Experimental antibody combo aims to boost immune attack on head and neck tumors
- Scientists hunt for blood markers to unmask hidden aggressive tumors
- Liver damage study in head and neck cancer abandoned after just 2 patients
- New antibody drug takes aim at Hard-to-Treat cancers